Download PDF Flyer
Impact Factor Current: 2.720
5 - Year: 3.238

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Latest Issue: Volume 19 , Issue 8 , 2019

Back Journal Home
Impact Factor
Web of Science Impact Factor

Current: 2.720
5 - Year: 3.238

Ranking & Category

  • ONCOLOGY 140th of 222

Topics Covered

1 Topics

View
Covered Diseases

1 Diseases

View

Aims & Scope

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.

Current Cancer Drug Targets publishes original research articles, letters, reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.

As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Abstracted/Indexed in


Science Citation Index Expanded (SciSearch®), Journal Citation Reports/Science Edition, InCites, Index to Scientific Reviews®, Biochemistry & Biophysics Citation Index®, Biotechnology Citation Index, ISI Alerting Services, Prous Science Integrity, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, MEDLINE/PubMed/Index Medicus, Scopus, EMBASE, Chemical Abstracts Service/SciFinder, ProQuest, ChemWeb, Google Scholar, BIOBASE, PubsHub, Index Copernicus, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO, British Library, Ulrich's Periodicals Directory and JournalTOCs.

Abstracted/Indexed in
Announcements
Endorsement(s)

"This journal fills an important need in providing reviews, covering the moving area of new cancer drug targets."

Paul Workman
CRC Centre for Cancer Therapeutics, England

Authors' Comments

“"I would like to express my sincere thanks for the services by Bentham Science.
I'm really happy with my submission in your Journal and hope that I will able to continue submitting manuscripts to your journal"”

Saeed Samarghandian
(Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran)

© 2019 Bentham Science Publishers